Literature DB >> 1571199

SIV/HIV recombinants and their use in studying biological properties.

R Shibata1, A Adachi.   

Abstract

A series of chimeric clones between human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency viruses (SIV) were constructed. Viability of the recombinant viruses was dependent on the position of recombination. Infectious chimeric viruses between HIV-1 and SIVAGM (isolated from an African green monkey) and those between HIV-1 and SIVMAC (isolated from a rhesus monkey) were examined for host cell tropism. Viral determinants that restrict the replication of SIVAGM in human MT-4 cells and that of HIV-1 in macaque monkey peripheral blood mononuclear cells (PBMC) mapped to the 5' half of the virus genome. One HIV-1/SIVMAC chimera which contained the HIV-1 env gene was shown to replicate in macaque PBMC in vitro and to infect macaque monkeys in vivo. This HIV-1/SIVMAC chimera will be useful for a variety of AIDS pathogenesis and vaccine studies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1571199     DOI: 10.1089/aid.1992.8.403

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  17 in total

1.  Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo.

Authors:  Y Ye; Z H Si; J P Moore; J Sodroski
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Functional analysis of vif genes derived from various primate immunodeficiency viruses.

Authors:  Y Yamamoto; Y Saito; S Iida; J Asano; S Sone; A Adachi
Journal:  Virus Genes       Date:  1997       Impact factor: 2.332

3.  Pathogenic conversion of live attenuated simian immunodeficiency virus vaccines is associated with expression of truncated Nef.

Authors:  E T Sawai; M S Hamza; M Ye; K E Shaw; P A Luciw
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

4.  Human and simian immunodeficiency virus capsid proteins are major viral determinants of early, postentry replication blocks in simian cells.

Authors:  Christopher M Owens; Peter C Yang; Heinrich Göttlinger; Joseph Sodroski
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

5.  Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques.

Authors:  S V Joag; Z Li; L Foresman; E B Stephens; L J Zhao; I Adany; D M Pinson; H M McClure; O Narayan
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

6.  Animal model of mucosally transmitted human immunodeficiency virus type 1 disease: intravaginal and oral deposition of simian/human immunodeficiency virus in macaques results in systemic infection, elimination of CD4+ T cells, and AIDS.

Authors:  S V Joag; I Adany; Z Li; L Foresman; D M Pinson; C Wang; E B Stephens; R Raghavan; O Narayan
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

Review 7.  Compatibility of Tat and Rev transactivators in the primate lentiviruses.

Authors:  H Sakai; J Sakuragi; S Sakuragi; M Kawamura; A Adachi
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

Review 8.  Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials.

Authors:  Devon J Shedlock; Guido Silvestri; David B Weiner
Journal:  Nat Rev Immunol       Date:  2009-10       Impact factor: 53.106

Review 9.  Neuroimmunity and the blood-brain barrier: molecular regulation of leukocyte transmigration and viral entry into the nervous system with a focus on neuroAIDS.

Authors:  Clarisa M Buckner; Aimée J Luers; Tina M Calderon; Eliseo A Eugenin; Joan W Berman
Journal:  J Neuroimmune Pharmacol       Date:  2006-04-13       Impact factor: 4.147

10.  Understanding restriction factors and intrinsic immunity: insights and lessons from the primate lentiviruses.

Authors:  Andrea Kirmaier; Annabel Krupp; Welkin E Johnson
Journal:  Future Virol       Date:  2014       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.